Bioavailability of the Tablet Dosage Form of a Benzimidazole Derivative Possessing Antiplatelet Activity

Bioavailability of the Tablet Dosage Form of a Benzimidazole Derivative Possessing Antiplatelet Activity

The bioavailability of the tablet dosage form of pharmaceutical substance RU-891, i.e., 9-(3,4-dihydroxyphenacyl)-2,3-dihydroimidazo[1,2- a ]benzimidazole hydrobromide, was investigated. The main pharmacokinetic parameters were determined. The relative bioavailability index was estimated at 93.98%....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmaceutical chemistry journal 2022-11, Vol.56 (8), p.1024-1026
Hauptverfasser: Spasov, A. A., Kucheryavenko, A. F., Gaidukova, K. A., Sirotenko, V. S., Smirnova, L. A., Ryabukha, A. F., Kuznetsov, K. A., Velikopol’skaya, M. V.
Format: Artikel
Sprache:eng
Schlagworte:
Medical colleges
Medicine
Organic Chemistry
Pharmacology/Toxicology
Pharmacy
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The bioavailability of the tablet dosage form of pharmaceutical substance RU-891, i.e., 9-(3,4-dihydroxyphenacyl)-2,3-dihydroimidazo[1,2- a ]benzimidazole hydrobromide, was investigated. The main pharmacokinetic parameters were determined. The relative bioavailability index was estimated at 93.98%. No evidence of drug accumulation from an RU-891 270-mg tablet dosage form was detected in rabbits upon threefold administration at a dose of 23 mg/kg.
ISSN:0091-150X
1573-9031
DOI:10.1007/s11094-022-02746-4